BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2060 related articles for article (PubMed ID: 30662558)

  • 1. Engineering Nanoparticles for Targeted Remodeling of the Tumor Microenvironment to Improve Cancer Immunotherapy.
    Gao S; Yang D; Fang Y; Lin X; Jin X; Wang Q; Wang X; Ke L; Shi K
    Theranostics; 2019; 9(1):126-151. PubMed ID: 30662558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential applications of nanoparticles for tumor microenvironment remodeling to ameliorate cancer immunotherapy.
    Bai Y; Wang Y; Zhang X; Fu J; Xing X; Wang C; Gao L; Liu Y; Shi L
    Int J Pharm; 2019 Oct; 570():118636. PubMed ID: 31446027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanoparticles for tumor immunotherapy.
    Zang X; Zhao X; Hu H; Qiao M; Deng Y; Chen D
    Eur J Pharm Biopharm; 2017 Jun; 115():243-256. PubMed ID: 28323111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimizing Tumor Microenvironment for Cancer Immunotherapy: β-Glucan-Based Nanoparticles.
    Zhang M; Kim JA; Huang AY
    Front Immunol; 2018; 9():341. PubMed ID: 29535722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
    Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
    Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Taking a Full Snapshot of Cancer Biology: Deciphering the Tumor Microenvironment for Effective Cancer Therapy in the Oncology Clinic.
    Dzobo K
    OMICS; 2020 Apr; 24(4):175-179. PubMed ID: 32176591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanoengineered Immune Niches for Reprogramming the Immunosuppressive Tumor Microenvironment and Enhancing Cancer Immunotherapy.
    Phuengkham H; Ren L; Shin IW; Lim YT
    Adv Mater; 2019 Aug; 31(34):e1803322. PubMed ID: 30773696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor-intrinsic signaling pathways: key roles in the regulation of the immunosuppressive tumor microenvironment.
    Yang L; Li A; Lei Q; Zhang Y
    J Hematol Oncol; 2019 Nov; 12(1):125. PubMed ID: 31775797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combining Nanomedicine and Immunotherapy.
    Shi Y; Lammers T
    Acc Chem Res; 2019 Jun; 52(6):1543-1554. PubMed ID: 31120725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Engineered Nanomaterials for Tumor Immune Microenvironment Modulation in Cancer Immunotherapy.
    Xing H; Li X
    Chemistry; 2024 Jun; 30(32):e202400425. PubMed ID: 38576219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Small molecule immunomodulation: the tumor microenvironment and overcoming immune escape.
    Osipov A; Saung MT; Zheng L; Murphy AG
    J Immunother Cancer; 2019 Aug; 7(1):224. PubMed ID: 31439034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunosuppressive cells in tumor immune escape and metastasis.
    Liu Y; Cao X
    J Mol Med (Berl); 2016 May; 94(5):509-22. PubMed ID: 26689709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulating barriers of tumor microenvironment through nanocarrier systems for improved cancer immunotherapy: a review of current status and future perspective.
    Lan H; Zhang W; Jin K; Liu Y; Wang Z
    Drug Deliv; 2020 Dec; 27(1):1248-1262. PubMed ID: 32865029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic Regulation of Tregs in Cancer: Opportunities for Immunotherapy.
    Wang H; Franco F; Ho PC
    Trends Cancer; 2017 Aug; 3(8):583-592. PubMed ID: 28780935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel approaches in cancer immunotherapy.
    Subramaniam DS; Liu SV; Giaccone G
    Discov Med; 2016 Apr; 21(116):267-74. PubMed ID: 27232512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of autophagy fires up the cold tumor microenvironment to improve cancer immunotherapy.
    Jin Z; Sun X; Wang Y; Zhou C; Yang H; Zhou S
    Front Immunol; 2022; 13():1018903. PubMed ID: 36300110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies.
    Kato D; Yaguchi T; Iwata T; Morii K; Nakagawa T; Nishimura R; Kawakami Y
    Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(1):68-77. PubMed ID: 28539557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor microenvironment remodeling via targeted depletion of M2-like tumor-associated macrophages for cancer immunotherapy.
    Cao Y; Qiao B; Chen Q; Xie Z; Dou X; Xu L; Ran H; Zhang L; Wang Z
    Acta Biomater; 2023 Apr; 160():239-251. PubMed ID: 36774974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Harnessing nanomedicine to overcome the immunosuppressive tumor microenvironment.
    Sun B; Hyun H; Li LT; Wang AZ
    Acta Pharmacol Sin; 2020 Jul; 41(7):970-985. PubMed ID: 32424240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nano-delivery of fraxinellone remodels tumor microenvironment and facilitates therapeutic vaccination in desmoplastic melanoma.
    Hou L; Liu Q; Shen L; Liu Y; Zhang X; Chen F; Huang L
    Theranostics; 2018; 8(14):3781-3796. PubMed ID: 30083259
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 103.